Breaking News, Collaborations & Alliances

Chime Biologics Partners with Leads Biolabs and BeiGene

Alliance aims to accelerate LBL-007 mAb development and manufacturing for speedy clinical advancement.

Chime Biologics, a biologics contract development and manufacturing organization (CDMO), has established 3-way strategic cooperation with Leads Biolabs and BeiGene to accelerate LBL-007 mAb development and manufacturing for speedy clinical advancement. LBL-007 is a novel antibody targeting the LAG-3 pathway developed independently by Leads Biolabs. Previously, Leads Biolabs and BeiGene reached an authorization and cooperation agreement. Leads Biolabs grants LBL-007 exclusive global develop...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters